Minerva Neurosciences | NERV - Cost Of Sales


Minerva Neurosciences reported 386K in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Adma Biologics USD 50.4M 8.24M Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
AstraZeneca USD 3.27B 471M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Cipla INR 29.1B 1.16B Dec/2025
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 3.54M 1.89M Dec/2025
CSL USD 3.87B 2.08B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Grifols EUR 1.51B 184.45M Dec/2025
Halozyme Therapeutics USD 102.15M 29.14M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Minerva Neurosciences 386K 31K Jun/2024
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Novavax USD 22.1M 608K Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Roche Holding CHF 8.48B 4.61B Dec/2025
Sanofi EUR 4.29B 421M Dec/2025
Takeda JPY 401.15B 184.07B Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024